Luye Group 
Welcome,         Profile    Billing    Logout  
 36 Products   29 Diseases   36 Products   123 Trials   3033 News 


«12345678910111213...3334»
  • ||||||||||  EPC-002 / Elpis Biopharma
    Journal:  Immunogenicity and efficacy analyses of EPC002, ECA006, and EPCP009 protein subunit combinations as tuberculosis vaccine candidates. (Pubmed Central) -  Jun 14, 2023   
    The in vitro mycobacterial growth inhibition assay demonstrated that EPCP009m inhibited Mycobacterium tuberculosis (Mtb) growth most strongly, followed by EPCP009f, which was significantly better than that of the other four vaccine candidates. These results indicated that EPCP009m containing four immunodominant antigens exhibited better immunogenicity and Mtb growth inhibition in vitro and may be a promising candidate vaccine for the control of TB.
  • ||||||||||  Opdivo (nivolumab) / BMS, Zepzelca (lurbinectedin) / PharmaMar, Jazz, Yervoy (ipilimumab) / BMS
    Enrollment open, Metastases:  LINNOVATE: Lurbinectedin, Ipilimumab and Nivolumab for Soft Tissue Sarcoma (clinicaltrials.gov) -  Jun 9, 2023   
    P1/2,  N=40, Recruiting, 
    These results indicated that EPCP009m containing four immunodominant antigens exhibited better immunogenicity and Mtb growth inhibition in vitro and may be a promising candidate vaccine for the control of TB. Not yet recruiting --> Recruiting
  • ||||||||||  Pozenveo (poziotinib) / Assertio
    Enrollment change, Trial completion date, Trial termination, Trial primary completion date:  A Study to Allow Continued Dosing and/or Follow-up of Patients Who Have Had Previous Exposure to Poziotinib (clinicaltrials.gov) -  May 25, 2023   
    P2,  N=7, Terminated, 
    Not yet recruiting --> Recruiting N=20 --> 7 | Trial completion date: Apr 2026 --> Mar 2023 | Active, not recruiting --> Terminated | Trial primary completion date: Oct 2023 --> Mar 2023; Business reasons, not related to safety.
  • ||||||||||  Baituowei (goserelin acetate sustained-release microspheres for injection) / Luye Group, BeiGene
    Trial completion:  Pharmacokinetics, Pharmacodynamics and Safety of LY01005 in Patients With Prostate Cancer Compared to ZOLADEX (clinicaltrials.gov) -  May 16, 2023   
    P1,  N=23, Completed, 
    N=20 --> 7 | Trial completion date: Apr 2026 --> Mar 2023 | Active, not recruiting --> Terminated | Trial primary completion date: Oct 2023 --> Mar 2023; Business reasons, not related to safety. Active, not recruiting --> Completed
  • ||||||||||  Ruoxinlin (toludesvenlafaxine extended release) / Luye Group
    Preclinical, Journal, IO biomarker:  The effect of triple reuptake inhibitor toludesvenlafaxine on neurological function in cerebral ischemic rats. (Pubmed Central) -  May 8, 2023   
    The application of the specific CREB inhibitor, compound 666-15, could reverse the anti-ischemic cerebral injury of Tdv in MCAO/R rats. Tdv ameliorated cerebral ischemic injury through reducing neuronal apoptosis and increasing the expression of BDNF via the activation of CREB pathway.
  • ||||||||||  rotigotine XR microspheres (LY03003) / Luye Group
    Trial completion, Trial completion date:  A Study to Evaluate the Effectiveness and Safety of LY03003 in Patients With Early Primary PD (clinicaltrials.gov) -  May 6, 2023   
    P3,  N=294, Completed, 
    Tdv ameliorated cerebral ischemic injury through reducing neuronal apoptosis and increasing the expression of BDNF via the activation of CREB pathway. Recruiting --> Completed | Trial completion date: May 2022 --> Sep 2022
  • ||||||||||  Lipusu (liposomal paclitaxel) / Luye Group
    Journal:  Transforming a Toxic Non-Ionizable Drug into an Efficacious Liposome via Ionizable Prodrug and Remote Loading Strategies against Malignant Breast Tumors. (Pubmed Central) -  May 2, 2023   
    Due to its non-ionizable and water-insoluble characteristics, the drug-loading efficiency of the marketable PTX lipos, Lipusu, is only 6.76%...A series of in vitro/vivo experiments indicated that PTXP lipos possess colloidal stability, prolonged blood circulation, high tumor site accumulation, potent anti-tumor effects, and safety. A combination of ionizable prodrugs and remote loading has proved to be an effective and simple strategy to achieve high liposomal encapsulation efficiency of poorly soluble non-ionizable drugs for clinical application.
  • ||||||||||  Zepzelca (lurbinectedin) / PharmaMar, Jazz
    Safety analysis of lurbinectedin versus topotecan in elderly patients. () -  Apr 26, 2023 - Abstract #ASCO2023ASCO_6374;    
    P2, P3
    With the limitations of cross-trial comparisons, lurbinectedin shows a clear advantage in terms of hematological toxicity compared with topotecan in patients ? 65 years old.
  • ||||||||||  Zepzelca (lurbinectedin) / PharmaMar, Jazz
    Efficacy and safety of lurbinectedin in elderly patients with relapsed SCLC. (On Demand | Hall A; Poster Bd # 218) -  Apr 26, 2023 - Abstract #ASCO2023ASCO_1977;    
    P2, P3
    Clinical trial information: NCT02454972, NCT02566993. >* Growth colony-stimulating factors were mandatory for both ATLANTIS treatment arms.** Nominal comparisons in ATLANTIS (small number of patients in basket trial)AEs, adverse events; CI, confidence interval; mo, months; OS, overall survival.
  • ||||||||||  LY03015 / Luye Group
    Enrollment open, Trial completion date, Trial primary completion date:  A Dose-escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetic of LPM3770164 in Healthy Subjects (clinicaltrials.gov) -  Apr 26, 2023   
    P1,  N=104, Recruiting, 
    Lurbinectedin provides an additional option from second-line for ES-SCLC, with efficacy outcomes comparable to that of historical treatments. Not yet recruiting --> Recruiting | Trial completion date: Jul 2023 --> Oct 2023 | Trial primary completion date: Jan 2023 --> Oct 2023
  • ||||||||||  Zepzelca (lurbinectedin) / PharmaMar, Jazz
    Enrollment open, Trial completion date, Trial primary completion date, Metastases:  Safety Tolerability Pharmacokinetic and Preliminary Efficacy in Chinese Advanced Solid Tumors Patients (clinicaltrials.gov) -  Apr 26, 2023   
    P1,  N=28, Recruiting, 
    Not yet recruiting --> Recruiting | Trial completion date: Jul 2023 --> Oct 2023 | Trial primary completion date: Jan 2023 --> Oct 2023 Not yet recruiting --> Recruiting | Trial completion date: Aug 2022 --> Dec 2024 | Trial primary completion date: Feb 2022 --> Dec 2024
  • ||||||||||  irinotecan hydrochloride liposome injection (LY01610) / Luye Group
    Enrollment closed, Trial completion date, Trial primary completion date:  Irinotecan Hydrochloride Liposome Injection (LY01610) For Small Cell Lung Cancer (clinicaltrials.gov) -  Apr 26, 2023   
    P2,  N=90, Active, not recruiting, 
    Not yet recruiting --> Recruiting | Trial completion date: Aug 2022 --> Dec 2024 | Trial primary completion date: Feb 2022 --> Dec 2024 Recruiting --> Active, not recruiting | Trial completion date: Sep 2022 --> Sep 2023 | Trial primary completion date: Jun 2022 --> Jun 2023
  • ||||||||||  irinotecan hydrochloride liposome injection (LY01610) / Luye Group
    Trial completion, Enrollment change, Metastases:  LY01610/CT-CHN-101: Irinotecan Hydrochloride Liposome Injection (LY01610) For Advanced Solid Tumors (clinicaltrials.gov) -  Apr 26, 2023   
    P1,  N=38, Completed, 
    Recruiting --> Active, not recruiting | Trial completion date: Sep 2022 --> Sep 2023 | Trial primary completion date: Jun 2022 --> Jun 2023 Unknown status --> Completed | N=111 --> 38
  • ||||||||||  paliperidone palmitate ER (LY03010) / Luye Group
    Trial completion:  Relative Bioavailability of LY03010 Compared to Listed Drug (clinicaltrials.gov) -  Apr 25, 2023   
    P1,  N=281, Completed, 
    Unknown status --> Completed | N=111 --> 38 Active, not recruiting --> Completed
  • ||||||||||  Zepzelca (lurbinectedin) / PharmaMar, Jazz
    #Lurbinectedin (Twitter) -  Apr 16, 2023   
  • ||||||||||  Ixempra (ixabepilone) - Otsuka, R / Pharm, Allarity Therap, epothilone D (BMS-241027) / BMS, utidelone (UTD1) / Beijing Biostar Technologies
    Review, Journal:  Epothilones as Natural Compounds for Novel Anticancer Drugs Development. (Pubmed Central) -  Apr 13, 2023   
    In recent years innovative synthetic strategies resulted in the synthesis of new epothilone derivatives with improved activity against refractory tumors with better activities when compared to ixabepilone or taxol. These compounds together with specific delivery mechanisms could be developed in anti-cancer drugs.
  • ||||||||||  Pozenveo (poziotinib) / Assertio
    Trial completion date, Trial primary completion date, EGFR exon 20, HER2 exon 20, Metastases:  NCI-2017-00831: Poziotinib in EGFR Exon 20 Mutant Advanced NSCLC (clinicaltrials.gov) -  Apr 5, 2023   
    P2,  N=116, Active, not recruiting, 
    Not yet recruiting --> Recruiting Trial completion date: Mar 2024 --> Sep 2024 | Trial primary completion date: Mar 2024 --> Sep 2024